FDA approves Leqembi Iqlik subcutaneous initiation dose for Alzheimer's disease

FDA approves subcutaneous self-injection initiation dosing for Leqembi (lecanemab), Alzheimer's anti-amyloid monoclonal antibody, delivered via autoinjector from treatment start. The approval reduces clinic visit burden and infusion centre dependency whilst maintaining biomarker and clinical efficacy equivalent to intravenous administration.

This Wire brief sits within Fusion42's coverage of Digital Health.